Literature DB >> 30014288

Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens.

Sebastian Fernandez-Pol1, Matt van de Rijn2, Yasodha Natkunam2, Gregory W Charville2.   

Abstract

PAX7 has been recently demonstrated to be a highly sensitive marker for Ewing sarcoma, and thus far has only been shown to label a relatively small set of other mesenchymal neoplasms. Because the processing of bone marrow core biopsies can often hinder the performance of immunohistochemical stains, we set out to determine if our laboratory's PAX7 staining protocol effectively detects Ewing sarcoma in Bouin's fixed, decalcified bone marrow core biopsies. We stained ten core biopsies involved by Ewing sarcoma, nine non-involved core biopsies, and 13 core biopsies involved by histologic mimics of Ewing sarcoma. Only the ten biopsies involved by Ewing sarcoma and four biopsies with rhabdomyosarcoma showed strong nuclear PAX7 staining. None of the other tumors demonstrated PAX7 expression. This study demonstrates that the PAX7 staining protocol used in our laboratory is a useful marker for Ewing sarcoma and other PAX7-positive tumors in decalcified bone marrow core biopsies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30014288     DOI: 10.1007/s00428-018-2410-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  9 in total

1.  Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood.

Authors:  M N Dworzak; G Fritsch; P Buchinger; C Fleischer; D Printz; A Zellner; A Schöllhammer; G Steiner; P F Ambros; H Gadner
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

2.  ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.

Authors:  Markku Miettinen; Zeng-Feng Wang; Anders Paetau; Shyh-Han Tan; Albert Dobi; Shiv Srivastava; Isabell Sesterhenn
Journal:  Am J Surg Pathol       Date:  2011-03       Impact factor: 6.394

3.  Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.

Authors:  Oliver Bock; Kais Hussein; Michael Neusch; Jerome Schlué; Birgitt Wiese; Hans Kreipe
Journal:  Eur J Haematol       Date:  2006-08-23       Impact factor: 2.997

4.  Surface antigenic determinants on human pluripotent and unipotent hematopoietic progenitor cells.

Authors:  M P Bodger; C A Izaguirre; H A Blacklock; A V Hoffbrand
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

5.  A monoclonal antibody specific for immature human hemopoietic cells and T lineage cells.

Authors:  M P Bodger; G E Francis; D Delia; S M Granger; G Janossy
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

6.  PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours.

Authors:  Shunichi Toki; Susumu Wakai; Masaya Sekimizu; Taisuke Mori; Hitoshi Ichikawa; Akira Kawai; Akihiko Yoshida
Journal:  Histopathology       Date:  2018-08-02       Impact factor: 5.087

Review 7.  Ewing's sarcoma.

Authors:  Naomi J Balamuth; Richard B Womer
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

8.  EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma.

Authors:  Gregory W Charville; Wei-Lien Wang; Davis R Ingram; Angshumoy Roy; Dafydd Thomas; Rajiv M Patel; Jason L Hornick; Matt van de Rijn; Alexander J Lazar
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

9.  PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms.

Authors:  Gregory W Charville; Sushama Varma; Erna Forgó; Sarah N Dumont; Eduardo Zambrano; Jonathan C Trent; Alexander J Lazar; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2016-10       Impact factor: 6.394

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.